Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2016. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report primarily serves to incorporate a press release dated September 27, 2016, by reference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes versus prior periods are detailed in the text of this Form 6-K. The filing references an attached press release (Exhibit 99.1) for specific operational or strategic updates, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, risk factors, or details on contingencies. It solely confirms the issuance of a press release on September 27, 2016, and incorporates it into the company's Registration Statements on Forms F-3 and S-8.
Investor Verification Checklist
- Verify the actual content of the press release dated September 27, 2016 (Exhibit 99.1), as the summary text does not contain the news details.
- Confirm the registrant name is Galapagos NV, noting the discrepancy with the metadata label "Lakefront Biotherapeutics NV."
- Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, 333-208697, and 333-211834) for context on how this press release impacts ongoing offerings.